GlassScriptPhysician profile
Daniel C Roney
NPI 1487618690
$13,216.07
in general payments reported to CMS, 2019-2025
81 companies · $2,213 in 2025
The $2,213 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,266 · 2020: $1,568 · 2021: $2,187 · 2022: $1,820 · 2023: $2,019 · 2024: $2,144 · 2025: $2,213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,375.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,627.76 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,441.65 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,316.32 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,066.99 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $780.60 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Lilly USA, LLC | $749.99 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $457.29 | 2019-2024 | Trintellix |
| Glaxosmithkline, LLC. | $440.04 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $343.70 | 2019-2025 | Repatha, Otezla, Otezla |
| Antares Pharma, INC. | $328.68 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Janssen Pharmaceuticals, INC | $297.70 | 2019-2025 | Spravato |
| Merck Sharp & Dohme LLC | $270.49 | 2020-2024 | Belsomra, Steglatro, Gardasil 9 |
| Abbott Laboratories | $228.58 | 2021-2025 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $186.88 | 2019-2024 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $182.32 | 2021-2025 | Rexulti |
Show all 81 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Roney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.